Algo version: 0.98b
Enimmune corporation is listed at the TWO Exchange
Enimmune corporation [6564.TWO]
TWO Sector: Healthcare Industry:Biotechnology

Is Enimmune corporation stock a buy?

What Is The Conclusion?

Right now our advanced algorithms say:

Do the analyst corps agree?

Interesting Questions and Easy Answers!

We cannot find any recorded dividends paid in our systems.

Sorry, we do not have any analyst data for this ticker

We cannot find data for Enimmune corporation 10 years ago, but if you had invested on Friday 22nd of November 2019 when the price was TWD24.08, you would have made a profit of TWD4.52 per share or 18.77%

Yes, the average daily trading liquidity for Enimmune corporation is TWD40 450 thousand. You should therefore be able to get in and out of your positions relatively fast.

Enimmune corporation has a normal ratio of the business financed by loans. This puts the company at some risk in periods of high inflation where borrowing costs usually go up. The company is still not profitable, and high inflation will make it harder to become profitable as costs increase and consumer spending decreases.

We have calculated the inflation risk for Enimmune corporation to be high [0.85 of 1]

US inflation for August 2024 was 0.19%. Over the last 12 months, the US inflation is 2.59%. The 10-year treasury yield that indicates the future interest level is currently 4.41 and is up 0.05 over the last 30 days.